[1] Xie Y, Bowe B, Mokdad A H, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends?of chronic kidney disease epidemiology from 1990 to 2016 [J]. Kidney Int, 2018, 94(3): 567-581.
[2] Flagg A J. Chronic Renal Therapy [J]. Nurs Clin North Am, 2018, 53(4): 511-519.
[3] Vachharajani T J, Taliercio J J, Anvari E. New Devices and Technologies for Hemodialysis Vascular Access: A Review [J]. Am J Kidney Dis, 2021, 78(1): 116-124.
[4] Lok C E, Huber T S, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update [J]. Am J Kidney Dis, 2020, 75(4 Suppl 2): S1-s164.
[5] Wan Q, Li L, Yang S, Chu F. Impact of Statins on Arteriovenous Fistulas Outcomes: A Meta-Analysis [J]. Ther Apher Dial, 2018, 22(1): 67-72.
[6] Chang C J, Ko P J, Hsu L A, et al. Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: implication in prevention of restenosis [J]. Am J Kidney Dis, 2004, 43(1): 74-84.
[7] Dember L M, Beck G J, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial [J]. Jama, 2008, 299(18): 2164-2171.
[8] Yeh C H, Huang T S, Wang Y C, et al. Effects of Antiplatelet Medication on Arteriovenous Fistula Patency After Surgical Thrombectomy [J]. Curr Vasc Pharmacol, 2016, 14(4): 353-359.
[9] Wiesbauer F, Kaun C, Zorn G, et al. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins [J]. Br J Pharmacol, 2002, 135(1): 284-292.
[10] Martinez L, Duque J C, Escobar L A, et al. Distinct impact of three different statins on arteriovenous fistula outcomes: a retrospective analysis [J]. J Vasc Access, 2016, 17(6): 471-476.
[11] Li Y, Cui W, Wang J, et al. Factors associated with dysfunction of autogenous arteriovenous fistula in patients with maintenance hemodialysis: a retrospective study [J]. Ann Palliat Med, 2021, 10(4): 4047-4054.
[12] Zhang F, Li J, Yu J, et al. Risk factors for arteriovenous fistula dysfunction in hemodialysis patients: a retrospective study [J]. Sci Rep, 2023, 13(1): 21325.
[13] Misskey J, Hamidizadeh R, Faulds J, et al. Influence of artery and vein diameters on autogenous arteriovenous access patency [J]. J Vasc Surg, 2020, 71(1): 158-172.e151.
[14] Wu Y, Wang F, Wang T, et al. Association of Retinol-Binding Protein 4 with Arteriovenous Fistula Dysfunction in Hemodialysis Patients [J]. Blood Purif, 2021, 50(6): 906-913.
[15] 余燕燕, 左君秋, 周红霞, 等. 尿毒症血液透析患者血清Lp-PLA2、FGF-23与自体动静脉内瘘成熟不良的关系研究 [J]. 现代生物医学进展, 2024, 24(03): 512-516.
[16] 王涛, 王蕴若, 王惠新, 等. 维持性血液透析患者AVF早期失功的危险因素分析 [J]. 国际泌尿系统杂志, 2024, 44(01): 121-125.
[17] 殷效龙, 叶建华, 张汀, 等. 血液透析患者自体动静脉内瘘早期失功的相关因素研究 [J]. 宁夏医学杂志, 2024, 46(01): 12-15.
[18] Gameiro J, Ibeas J. Factors affecting arteriovenous fistula dysfunction: A narrative review [J]. J Vasc Access, 2020, 21(2): 134-147.
[19] Weiss M F, Scivittaro V, Anderson J M. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access [J]. Am J Kidney Dis, 2001, 37(5): 970-980.
[20] Lin C F, Chiou H Y, Chang Y H, et al. Risk of arteriovenous fistula failure associated with hypnotic use in hemodialysis patients: a nested case-control study [J]. Pharmacoepidemiol Drug Saf, 2016, 25(8): 889-897.
[21] Windus D W. Permanent vascular access: a nephrologist's view [J]. Am J Kidney Dis, 1993, 21(5): 457-471.
[22] Ma S, Duan S, Liu Y, Wang H. Intimal Hyperplasia of Arteriovenous Fistula [J]. Ann Vasc Surg, 2022, 85: 444-453.
[23] Palumbo R, Dominijanni S, Centi A, et al. Hemodynamic impact of VASQ device in vascular access creation [J]. J Vasc Access, 2022, 23(1): 105-108.
[24] Dillavou E D, Lucas J F, Woodside K, et al. VasQ U.S. pivotal study demonstrates the safety and effectiveness of an external vascular support for arteriovenous fistula creation [J]. J Vasc Surg, 2023, 78(5): 1302-1312.e1303.
[25] Glickman M. Optiflow anastomotic device for hemodialysis vascular access creation [J]. J Vasc Access, 2017, 18(Suppl. 1): 84-87.
[26] Yildiz I. The Efficacy of Paclitaxel Drug-Eluting Balloon Angioplasty Versus Standard Balloon Angioplasty in Stenosis of Native Hemodialysis Arteriovenous Fistulas: An Analysis of Clinical Success, Primary Patency and Risk Factors for Recurrent Dysfunction [J]. Cardiovasc Intervent Radiol, 2019, 42(5): 685-692.
[27] Tang T Y, Chong T T, Yap C J Q, et al. Intervention with selution SLR? Agent Balloon for Endovascular Latent Limus therapy for failing AV Fistulas (ISABELLA) Trial: Protocol for a pilot clinical study and pre-clinical results [J]. J Vasc Access, 2023, 24(2): 289-299.
[28] Somarathna M, Hwang P T, Millican R C, et al. Nitric oxide releasing nanomatrix gel treatment inhibits venous intimal hyperplasia and improves vascular remodeling in a rodent arteriovenous fistula [J]. Biomaterials, 2022, 280: 121254.
[29] Sadaghianloo N, Contenti J, Declemy S, et al. Hypoxia and hypoxia-inducible factors promote the development of neointimal hyperplasia in arteriovenous fistula [J]. J Physiol, 2021, 599(8): 2299-2321.
[30] Barcena A J R, Perez J V D, Bernardino M R, et al. Bioresorbable Mesenchymal Stem Cell-Loaded Electrospun Polymeric Scaffold Inhibits Neointimal Hyperplasia Following Arteriovenous Fistula Formation in a Rat Model of Chronic Kidney Disease [J]. Adv Healthc Mater, 2023, 12(26): e2300960.
[31] Barcena A J R, Perez J V D, Damasco J A, et al. Gold Nanoparticles for Monitoring of Mesenchymal Stem Cell-Loaded Bioresorbable Polymeric Wraps for Arteriovenous Fistulas [J]. bioRxiv, 2023.
[32] 郑倩卿, 温杏良, 董丽娟. 提高动静脉内瘘成熟质量的临床研究 [J]. 南方护理学报, 2001, (02): 35-36.
[33] 郑婕, 鄢艳, 陈钦开, 等. 壳聚糖抑制家兔动静脉内瘘内膜增生的实验研究 [J]. 中华肾脏病杂志, 2015, 31(5): 367-371.
[34] 占丹丹, 鄢艳, 苏晓霞, 等.壳聚糖对尿毒症患者血管平滑肌细胞增生的抑制作用及其机制[C]//中国医院协会血液净化中心管理分会.中国医院协会血液净化中心管理分会, 2016.
[35] Yan Y, Wu Q, Li J-h, et al. Chitosan inhibits vascular intimal hyperplasia via LINC01615/MIR-185-5p/PIK3R2 signaling pathway [J]. Gene, 2024, 892.
[36] Janicki K, Dmoszyńska A, Janicka L, et al. Influence of antiplatelet drugs on occlusion of arteriovenous fistula in uraemic patients [J]. Int Urol Nephrol, 1992, 24(1): 83-89.
[37] Dmoszyńska A, Janicki K, Janicka L, et al. Influence of indobufen on occlusion of arteriovenous fistulas and some platelet activity in intermittent peritoneal dialysis patients [J]. Pol J Pharmacol, 1996, 48(3): 327-329.
[38] Chang H H, Chang Y K, Lu C W, et al. Statins Improve Long Term Patency of Arteriovenous Fistula for Hemodialysis [J]. Sci Rep, 2016, 6: 22197.
[39] Cui J, Kessinger C W, Jhajj H S, et al. Atorvastatin Reduces In Vivo Fibrin Deposition and Macrophage Accumulation, and Improves Primary Patency Duration and Maturation of Murine Arteriovenous Fistula [J]. J Am Soc Nephrol, 2020, 31(5): 931-945.
[40] Shi Q P, Luo X Y, Zhang B, et al. Effect of indobufen vs. aspirin on platelet accumulation in patients with stable coronary heart disease after percutaneous coronary intervention: An open-label crossover study [J]. Front Pharmacol, 2022, 13: 950719.
[41] Lee J Y, Sung K C, Choi H I. Comparison of aspirin and indobufen in healthy volunteers [J]. Platelets, 2016, 27(2): 105-109.
[42] Pan Y, Meng X, Yuan B, et al. Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial [J]. Lancet Neurol, 2023, 22(6): 485-493.
[43] Eligini S, Violi F, Banfi C, et al. Indobufen inhibits tissue factor in human monocytes through a thromboxane-mediated mechanism [J]. Cardiovasc Res, 2006, 69(1): 218-226.
[44] Cerletti C, Manarini S, Colombo M, Tavani A. The (+)-enantiomer is responsible for the antiplatelet and anti-inflammatory activity of (+/-)-indobufen [J]. J Pharm Pharmacol, 1990, 42(12): 885-887.
[45] Li F, Xu D, Hou K, et al. Pretreatment of Indobufen and Aspirin and their Combinations with Clopidogrel or Ticagrelor Alleviates Inflammasome Mediated Pyroptosis Via Inhibiting NF-κB/NLRP3 Pathway in Ischemic Stroke [J]. J Neuroimmune Pharmacol, 2021, 16(4): 835-853.
[46] Liu F, Zhang H, Wu H, et al. The Effects of Indobufen on Micro-Inflammation and Peritoneal Transport Function in Patients Undergoing Continuous Ambulate Peritoneal Dialysis: A Prospective Randomized Controlled Study [J]. J Pharmacol Exp Ther, 2023, 384(2): 296-305.
[47] Liu J, Xu D, Xia N, et al. Anticoagulant Activities of Indobufen, an Antiplatelet Drug [J]. Molecules, 2018, 23(6).
[48] Wu H, Xu L, Zhao X, et al. Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial [J]. Circulation, 2023, 147(3): 212-222.
[49] Bai C, Li J X, Yu Y, et al. [A randomized controlled trial of indobufen versus aspirin in the prevention of bridging restenosis after coronary artery bypass grafting] [J]. Zhonghua Xin Xue Guan Bing Za Zhi, 2022, 50(5): 466-470.
[50] 邓觅. 吲哚布芬对维持性血液透析自体动静脉内瘘血栓形成的预防效果 [J]. 临床合理用药, 2024, 17(06): 77-80.
[51] 王薇, 谭小猛, 王梦秋. 吲哚布芬联合红外线照射在改善血液透析患者凝血状态 血管内皮功能和动静脉内瘘功能中的效果分析 [J]. 山西医药杂志, 2024, 53(02): 97-101.
[52] 林邱. 吲哚布芬在动静脉内瘘PTA术后疗效观察 [D]; 成都医学院, 2024.
[53] 谢娟, 李正胜, 卢晶晶, 等. 吲哚布芬预防血透患者动静脉内瘘血栓形成的临床观察; proceedings of the 贵州省中西医结合学会血液净化专业委员会成立大会暨国家级名老中医经验传承交流会, 中国贵州贵阳, F, 2017 [C].
[54] 谢娟, 李正胜, 卢晶晶, 等. 吲哚布芬预防血液透析患者动静脉内瘘血栓形成 [J]. 贵州医科大学学报, 2017, 42(05): 607-610.
[55] Lea A P, McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias [J]. Drugs, 1997, 53(5): 828-847.
[56] Violi F, Carnevale R, Pastori D, Pignatelli P. Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition [J]. Trends Cardiovasc Med, 2014, 24(4): 142-148.
[57] 王珠凤. 阿托伐他汀联合阿司匹林治疗高血压伴动脉粥样硬化的临床疗效分析 [J]. 中外医疗, 2024, 43(08): 100-103.
[58] 高琛, 陈恒文, 张跃. 康欣口服液联合阿托伐他汀治疗中老年冠心病心肌缺血的效果分析 [J]. 中国社区医师, 2024, 40(09): 116-118.
[59] 刘东霞. 阿托伐他汀联合非诺贝特治疗混合型高脂血症的效果分析 [J]. 中国社区医师, 2024, 40(09): 20-22.
[60] 郗有丽, 赵重博, 杨娜, 等. 基于代谢组学研究阿托伐他汀致非酒精性脂肪肝模型鼠肝损伤的作用机制 [J]. 实用药物与临床, 2024, 27(04): 241-247.
[61] 田飞, 戴红波, 王利. 依达拉奉右莰醇联合阿托伐他汀治疗脑梗死的效果 [J]. 中国药物滥用防治杂志, 2024, 30(04): 699-702.
[62] 沈燕, 达静静, 皮明婧, 等. 阿托伐他汀联合远红外线照射对动静脉内瘘血栓形成的保护作用 [J]. 中华临床医师杂志(电子版), 2015, 9(17): 3175-3179.
[63] Yin Z, You S, Zhang S, et al. Atorvastatin rescues vascular endothelial injury in hypertension by WWP2-mediated ubiquitination and degradation of ATP5A [J]. Biomed Pharmacother, 2023, 166: 115228.
[64] Sena C M, Matafome P, Louro T, et al. Effects of atorvastatin and insulin in vascular dysfunction associated with type 2 diabetes [J]. Physiol Res, 2014, 63(2): 189-197.
[65] Chen C, Song C, Zhang D, et al. Effect of resveratrol combined with atorvastatin on re-endothelialization after drug-eluting stents implantation and the underlying mechanism [J]. Life Sci, 2020, 245: 117349.
[66] Lunder M, Jani? M, ?iberna L, et al. A low-dose atorvastatin and losartan combination directly improves aortic ring relaxation and diminishes ischaemic-reperfusion injury in isolated rat hearts [J]. Med Sci Monit, 2012, 18(9): Br366-374.
[67] Chen J, Song M, Qian D, et al. Atorvastatin rescues pulmonary artery hypertension by inhibiting the AKT/ERK-dependent PDGF-BB/HIF-1α axis [J]. Panminerva Med, 2024, 66(1): 4-9.
